Core Points - COSCIENS Biopharma Inc. has appointed Peter H. Puccetti as Interim Chief Executive Officer, succeeding Anna Biehn [1][2] - The leadership transition is part of the company's efforts to reduce costs and streamline its organizational structure while aligning resources with strategic priorities [2] - Puccetti aims to strengthen operational performance and drive shareholder value in his new role [2] Company Overview - COSCIENS is a life science company focused on natural ingredients and pharmaceutical solutions, with a diverse portfolio [3] - The company develops natural, plant-based active ingredients and commercializes pharmaceutical and diagnostic products [3] - COSCIENS' lead pharmaceutical product, Macimorelin, is the first FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3] Stock Information - COSCIENS' common shares are listed on the Toronto Stock Exchange under the symbol "CSCI" and have a trading symbol "CSCIF" for the OTC market in the United States [4]
COSCIENS Biopharma Inc. Announces Leadership Change